SCHEMBL472411

SCHEMBL472411

Cc1ncoc1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.49
▸ IMPDH2 P12268 2/20 0.47
▸ IMPDH1 P20839 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.44
▸ NOTUM Q6P988 1/20 0.41
▸ MAPK14 Q16539 2/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.40
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ NR1H4 Q96RI1 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.35
▸ LTA4H P09960 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ POLB P06746 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15929467 0.83 IMPDH2 (0.50) IMPDH2IMPDH1KDM4ENOTUMMAPK14
SCHEMBL3998459 0.80 IMPDH2 (0.50) GAAIMPDH2IMPDH1MAPK14NPC1
SCHEMBL472419 0.80 IMPDH2 (0.47) GAAIMPDH2IMPDH1KDM4EMAPK14
SCHEMBL6168845 0.80 IMPDH2 (0.47) GAAIMPDH2IMPDH1KDM4EMAPK14
SCHEMBL472455 0.80 MAPK14 (0.54) IMPDH2IMPDH1NOTUMMAPK14NPC1
SCHEMBL472514 0.79 AHR (0.45) IMPDH2IMPDH1NOTUMMAPK14NPC1
SCHEMBL13815981 0.79 IMPDH2 (0.43) GAAIMPDH2IMPDH1KDM4EMAPK14
SCHEMBL343219 0.79 ADORA2A (0.50) IMPDH2IMPDH1KDM4ENOTUMMAPK14
SCHEMBL344928 0.78 IMPDH2 (0.46) GAAIMPDH2IMPDH1KDM4ENPC1
SCHEMBL9953638 0.78 NOTUM (0.47) IMPDH2NOTUMMAPK14NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789089-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2017-10-17 — — US disclosed
EP-2412372-A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases Abbott Laboratories (US) 2012-02-01 — — EP disclosed
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 — — US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 — — EP disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 — — EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 — — US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 GAA 3675/4885IMPDH2 4461/4885IMPDH1 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback